卖什么
We use human data and AI to develop better drugs faster.
商业模式拆解
买家：谁掌握预算？
未核实R&D, translational and clinical development leaders at pharma and biotech.
触发点：什么让他们现在购买？
Low clinical success rates; enriching a Parkinson's trial with vBx-1.0 lifts responders from 52% to 69%, cutting required enrollment 43%.
工作流：什么输入变成什么输出？
Platform used for target discovery, target characterization, biomarker identification and patient stratification; vBx foundation model produces a 'virtual biopsy' from a routine blood draw.
经济账：省了什么，怎么收费？
Pharma partnerships built on proprietary brain data and models; $1.6B in partnerships with top-20 pharma claimed.
渠道：怎么接触到客户？
Business-development partnerships and platform access via Get in touch.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2015 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.